Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauro Schechter

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Sexually Transmitted Diseases|April 14, 2017
International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic StatusHong-Ha M Truong, Megha Mehrotra, Orlando Montoya, et al.
Plos Medicine|November 5, 2004
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Frank van Leth, Prahpan Phanuphak, Erik Stroes, et al.
The New England Journal of Medicine|January 18, 2013
Short-course antiretroviral therapy in primary HIV infection, Sarah Fidler, Kholoud Porter, et al.
Vaccine|November 21, 2009
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trialsT Christopher Mast, Lisa Kierstead, Swati B Gupta, et al.
Plos One|June 10, 2010
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin AmericaCarina Cesar, Bryan E Shepherd, Alejandro J Krolewiecki, et al.
AIDS (London, England)|February 7, 2014
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxisMarc M Solomon, Javier R Lama, David V Glidden, et al.
Journal of Virus Eradication|July 11, 2024
Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trialJasmini Alagaratnam, Wolfgang Stöhr, Elizabeth Hamlyn, et al.
Plos One|September 26, 2013
Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosisClaudia P Cortes, Firas H Wehbe, Catherine C McGowan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 27, 2017
Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized TrialJennifer F Hoy, Birgit Grund, Mollie Roediger, et al.
Elife|September 14, 2014
HIV-1 DNA predicts disease progression and post-treatment virological controlJames P Williams, Jacob Hurst, Wolfgang Stöhr, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Sexually Transmitted Diseases|April 14, 2017
International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic StatusHong-Ha M Truong, Megha Mehrotra, Orlando Montoya, et al.
Plos Medicine|November 5, 2004
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Frank van Leth, Prahpan Phanuphak, Erik Stroes, et al.
The New England Journal of Medicine|January 18, 2013
Short-course antiretroviral therapy in primary HIV infection, Sarah Fidler, Kholoud Porter, et al.
Vaccine|November 21, 2009
International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trialsT Christopher Mast, Lisa Kierstead, Swati B Gupta, et al.
Plos One|June 10, 2010
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin AmericaCarina Cesar, Bryan E Shepherd, Alejandro J Krolewiecki, et al.
AIDS (London, England)|February 7, 2014
Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxisMarc M Solomon, Javier R Lama, David V Glidden, et al.
Journal of Virus Eradication|July 11, 2024
Impact of interrupting antiretroviral therapy started during primary HIV-1 infection on plasma neurofilament light chain protein, a marker of neuronal injury: The SPARTAC trialJasmini Alagaratnam, Wolfgang Stöhr, Elizabeth Hamlyn, et al.
Plos One|September 26, 2013
Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosisClaudia P Cortes, Firas H Wehbe, Catherine C McGowan, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 27, 2017
Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized TrialJennifer F Hoy, Birgit Grund, Mollie Roediger, et al.
Elife|September 14, 2014
HIV-1 DNA predicts disease progression and post-treatment virological controlJames P Williams, Jacob Hurst, Wolfgang Stöhr, et al.
Pageof 12